Latest from Sidney Kimmel Cancer Center at Jefferson

The Sidney Kimmel Cancer Center – Jefferson Health announces a collaboration with Driver, a first-of-its-kind global technology platform that connects cancer patients to the best treatments, which launched today in the United States and China.

Benjamin P. Levy, MD, highlights the pros and cons of the different platforms for circulating tumor DNA detection, as well as the benefits and limitations of liquid biopsies.

Leonard Gomella, MD, professor, chair, Department of Urology, director, Sidney Kimmel Cancer Center Network, Thomas Jefferson University Hospital, discusses the FDA approval of enzalutamide (Xtandi) for the treatment of men with nonmetastatic castration-resistant prostate cancer.

James L. Godwin, MD, physician, Sidney Kimmel Cancer Center, Thomas Jefferson Hospital, discusses immunotherapy efforts in prostate cancer.

Edouard J. Trabulsi, MD, FACS, professor, co-director, Multidisciplinary Genitourinary Oncology Center, Prostate Diagnostic Center, vice chair of research, director, Division of Urologic Oncology, Department of Urology, Sidney Kimmel Cancer Center, discusses postoperative radiation in patients with prostate cancer.
 

Edouard J. Trabulsi, MD, FACS, professor, co-director, Multidisciplinary Genitourinary Oncology Center, Prostate Diagnostic Center, vice chair of research, director, Division of Urologic Oncology, Department of Urology, Sidney Kimmel Cancer Center, defines locally advanced prostate cancer.

Robert B. Den, MD, associate professor of radiation oncology, Thomas Jefferson University Hospital, discusses the future of prostate cancer research.
 

The ongoing phase IIIb PRONOUNCE trial is seeking to determine if the gonadotropin-releasing hormone receptor antagonist degarelix (Firmagon) is more likely to reduce cardiovascular events in patients with advanced prostate cancer and CVD versus the GnRH agonist receptor leuprolide.